At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 141–150 of 576 results.
-
Cells that are "mismatch repair-deficient" (MMR-D) or "microsatellite instability-high" (MSI-H) are unable to repair mistakes made during cell growth. Women with MMR-D/MSI-H endometrial cancer tend not to respond well to the chemotherapy they receive after surgery. Researchers are exploring the use of the immunotherapy TSR-042 (also called dostarlimab) as an alternative to chemotherapy. Radiation therapy is also used after surgery for endometrial cancer.
-
Researchers want to see how well quizartinib works to treat acute myeloid leukemia (AML). The people in this study have AML that does not have a genetic change called FLT3-ITD. In addition, they have not yet had any treatment for AML.
-
DAY301 is a type of drug called an antibody-drug conjugate (ADC). ADCs are substances made up of a monoclonal antibody (special protein) linked to a drug. The antibody binds to specific proteins on certain types of cells, including cancer cells. The linked drug enters these cells and kills them. With ADCs, there is a lower risk of harming normal cells, since they usually do not have the target protein.
-
The purpose of this study is to assess the safety and effectiveness of the investigational drug ZEN003694 in people with advanced squamous cell lung cancer that continues to grow despite treatment and contains multiple copies of a gene called NSD3. ZEN003694 blocks a group of proteins called BET, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of lung cancer. ZEN003694 is taken orally (by mouth).
-
Researchers are assessing different doses of FT825 alone or with cetuximab to treat people with advanced solid tumors. Their tumors have high levels of the HER2 protein. Altered HER2 proteins can fuel cancer growth. 
-
Researchers are comparing several combination drug treatments for people with cancer of the stomach or gastroesophageal junction (GEJ). The people in this study have gastric or GEJ cancer that metastasized (spread) or is inoperable (cannot be surgically removed). In addition, their tumors make a protein called HER2.
-
This study is comparing two treatment regimens for advanced pancreatic cancer. The people in this study have pancreatic ductal adenocarcinoma that has metastasized (spread). They have not yet had treatment for advanced disease.
-
Researchers in this study want to compare sentinel lymph node biopsy surgery with standard neck dissection as part of the treatment for people with early-stage oral cavity (mouth) cancer. Sentinel lymph node biopsy is a procedure that removes a smaller number of lymph nodes from the neck because it uses an imaging agent to see which lymph nodes are most likely to have cancer. Standard elective neck dissection removes many of the lymph nodes in the neck but may reduce shoulder mobility and strength.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Myelofibrosis is a rare disease known as a myeloproliferative neoplasm. The bone marrow becomes scarred and cannot make enough blood cells, leading to anemia. Anemia is low number of red blood cells, causing tiredness and shortness of breath. Some people with myelofibrosis need regular transfusions of blood. In this study, researchers want to see if momelotinib given with luspatercept reduces the need for blood transfusions in these patients. Momelotinib works by blocking two proteins called JAK and ACVR1. When JAK proteins send too many signals, the body makes the wrong amount of blood cells. By blocking JAK, momelotinib may help your body make the right amount of blood cells. By targeting ACVR1, momelotinib may fight anemia. Momelotinib is taken orally (by mouth).  By improving red blood cell development, luspatercept may reduce the need for blood transfusions in people with transfusion-dependent myelofibrosis. Luspatercept is given by an injection under the skin.